Literature DB >> 25511959

Comprehensive therapy for hemangioma presenting with Kasabach-Merritt syndrome in the maxillofacial region.

Lixin Su1, Deming Wang2, Xindong Fan3.   

Abstract

PURPOSE: To summarize the characteristics of Kasabach-Merritt syndrome (KMS) and to evaluate the therapeutic effect of drug therapy combined with transarterial embolization. PATIENTS AND METHODS: From 2007 to 2011, 6 cases of KMS that underwent drug therapy and transarterial embolization were retrospectively analyzed, comprising of 3 male and 3 female patients; the ages of the patients ranged from 3 to 40 days. The lesions were located in the temporal region (1 of 6, 16.7%), parotid region (2 of 6, 33.3%), or submandibular region and neck (3 of 6, 50%). All the patients were followed for 12 to 18 months. Therapeutic outcomes were assessed by evaluating the platelet count, coagulation parameters, and size of the lesion.
RESULTS: Positive responses were visible shrinkage of the hemangioma or lightening of the skin color of the cutaneous tumor (or both) within 8 to 72 hours in 4 patients (66.67%). These occurred within 1 week in 5 patients (83.33%) and within 2 weeks in all patients (100%). The mean platelet count before treatment was 18,000/L (range, 8,000 to 33,000/L). After the first week of medical treatment, the mean platelet count increased to above 80,000/L in 5 patients (83.33%); it began to increase on the second day after embolization and reached 102,000/L in 1 patient (16.67%). All 6 cases (100%) showed good results with treatment. A 12- to 18-month follow-up evaluation was obtained for all treated patients, and no rebound growth or platelet count decreases were observed. No severe or obvious adverse complications were noted during all treatment courses.
CONCLUSIONS: For most hemangiomas presenting with KMS, good results can be obtained with systemic medical treatment. Transcatheter arterial embolization with polyvinyl alcohol particles combined with systemic medical treatment should be considered an efficacious and important therapeutic option for challenging cases.
Copyright © 2015 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25511959     DOI: 10.1016/j.joms.2014.07.037

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  5 in total

1.  Enucleation is Better for a Giant Hemangioma Proximal to the Hepatic Portal Vascular Structures.

Authors:  Chuan-Xing Wu; Wan-Yuan Bao; Feng Zhu
Journal:  Indian J Surg       Date:  2015-11-02       Impact factor: 0.656

Review 2.  Standards of care for Kasabach-Merritt phenomenon in China.

Authors:  Wei Yao; Ke-Lei Li; Zhong-Ping Qin; Kai Li; Jia-Wei Zheng; Xin-Dong Fan; Lin Ma; De-Kai Zhou; Xue-Jian Liu; Li Wei; Li Li; Mao-Zhong Tai; Jin-Hu Wang; Yi Ji; Lin Zhou; Hai-Jin Huang; Xiao-Yun Gao; Zhi-Jian Huang; Song Gu; He-Ying Yang
Journal:  World J Pediatr       Date:  2020-08-26       Impact factor: 2.764

3.  Interferon-alpha therapy for refractory kaposiform hemangioendothelioma: a single-center experience.

Authors:  Hai Wei Wu; Xuan Wang; Ling Zhang; Hai Guang Zhao; Yan An Wang; Li Xin Su; Xin Dong Fan; Jia Wei Zheng
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

4.  Excellent outcome of medical treatment for Kasabach-Merritt syndrome: a single-center experience.

Authors:  Jin Ah Kim; Young Bae Choi; Eun Sang Yi; Ji Won Lee; Ki Woong Sung; Hong Hoe Koo; Keon Hee Yoo
Journal:  Blood Res       Date:  2016-12-23

5.  Successful transarterial embolization with cellulose porous beads for occipital haemangioma in an infant with Kasabach-Merritt syndrome.

Authors:  Zaw Aung Khant; Toshinori Hirai; Osamu Ikeda; Eiji Furukoji; Yoshihito Kadota; Minako Azuma; Norihiro Shinkawa; Keiji Kitatani; Yoichi Mizutani; Kimihiko Endo; Yasuyuki Yamashita
Journal:  BJR Case Rep       Date:  2017-05-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.